Drugs / NS101
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05143463 | Nov 2021 → Aug 2022 | neurodegenerative disease | Neuracle Science Co., LTD. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06249919 | Jan 2024 → May 2026 overdue | sudden sensorineural hearing loss | Neuracle Science Co., LTD. | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07154485 Comparator | Oct 2025 → Aug 2027 expected | frontotemporal dementia | Hee-Jin Kim | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-10-29 | Reyon Pharmaceutical Co., Ltd. | Regulatory REYON Pharmaceutical’s Partner, Neuracle Science, Received Go-Ahead for Phase 1 Clinical Trial on New Antibody Drug for Dementia reyonpharm.co.kr ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-10-29 | Reyon Pharmaceutical Co., Ltd. | REYON Pharmaceutical’s Partner, Neuracle Science, Received Go-Ahead for Phase 1 Clinical Trial on New Antibody Drug for Dementia reyonpharm.co.kr ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NS101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05143463 ↗ |
| Action | Inhibit | “Inhibiting FAM19A5 function with NS101 increased spine density.” PMID 40691577 ↗ Jul 2025 |
| Modality | Monoclonal antibody | “anti FAM19A5 antibody” NCT07154485 ↗ |
| Route | Intravenous | “Intravenous administration of NS101 increased spine density in the prefrontal cortex of P301S mice” PMID 40691577 ↗ Jul 2025 |
| Target | FAM19A5 | “Inhibiting FAM19A5 function with NS101 increased spine density.” PMID 40691577 ↗ Jul 2025 |